Model‐Informed Dose Optimization in Pregnancy. (17th November 2020)

• Record Type: Journal Article
• Authors: Chaphekar, Nupur; Caritis, Steve; Venkataramanan, Raman
• Other Names: Arya Vikram guestEditor.; Venkatakrishnan Karthik guestEditor.
• Is Part Of: Journal of clinical pharmacology. Volume 60(2020)Supplement 1
• Page Start: S63
• Page End: S76
• Publication Date: 2020-11-17
• Subjects: drug exposure -- PBPK -- PopPK -- pregnancy; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.1777
• Languages: English
• ISSNs: 0091-2700

Abstract

Abstract: Pregnancy is associated with several physiological changes that can alter the pharmacokinetics (PK) and pharmacodynamics of drugs. These may require dosing changes in pregnant women to achieve drug exposures comparable to the nonpregnant population. There is, however, limited information available on the PK and pharmacodynamics of drugs used during pregnancy. Practical difficulties in performing PK studies and potential liability issues are often the reasons for the availability of limited information. Over the past several years, there has been a rapid development in the application of various modeling strategies such as population PK and physiologically based PK modeling to provide guidance on drug dosing in this special patient population. Population PK models rely on measured PK data, whereas physiologically based PK models integrate physiological, preclinical, and clinical data to quantify changes in PK of drugs in various patient populations. These modeling strategies offer a promising approach to identify the drugs with PK changes during pregnancy and guide dose adjustment in pregnant women. This review focuses on PBPK modeling to guide drug therpay in pregnancy.